Cook Medical’s Zilver PTX Trial shows sustained patency after 3 years
Cook Medical’s Zilver PTX demonstrated 70.7% primary patency in the superficial femoral artery at 36 months in patients who received the paclitaxel-eluting stent, ,according to newly released study results.
Read more
IDEV Technologies’s SUPERA 500 showed positive 2-year clinical outcomes
IDEV Technologies announced at the VIVA conference that its SUPERA peripheral stent system showed positive 2-year clinical outcomes in the SUPERA 500 registry.
The SUPERA 500 study represents a long-term registry that is used in femoropopliteal artery disease. SUPERA should now be considered a primary option for femoropopliteal arteries, principal investigator Dr. Dierk Scheinert said on behalf of the company.
Read more
